May 8, 2026 08:01AM BioCardia receives FDA guidance on two approval pathways for Helix catheter

Apr 28, 2026 08:01AM BioCardia receives Japanese patent allowance for Heart3D imaging software

Apr 20, 2026 08:04AM BioCardia receives positive PMDA feedback for CardiAMP therapy in Japan

Mar 17, 2026 06:01AM BioCardia receives FDA acceptance for Helix catheter pre-submission

Dec 3, 2025 08:01AM BioCardia elects Marvin Slosman to board, Richard Krasno completes term

Nov 24, 2025 08:15AM BioCardia names Farhan Shahab as vice president of quality

Nov 12, 2025 05:54PM BioCardia (BCDA) Misses Q3 EPS by 24c

Sep 23, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on BioCardiAa (BCDA)

Sep 22, 2025 08:03AM BioCardia holds preliminary consultation with Japan drug agency on heart therapy

Sep 18, 2025 07:00AM BioCardia reports positive results from heart therapy trial

Sep 16, 2025 09:07AM BioCardia announces public offering of up to 2.8 million shares and warrants

Aug 11, 2025 04:41PM BioCardia (BCDA) Misses Q2 EPS by 40c

Jul 24, 2025 09:02AM BioCardia requests Japan PMDA meeting for CardiAMP therapy approval pathway

Jun 25, 2025 08:04AM BioCardia (BCDA) Announces New United States Patent for Helix Biotherapeutic Delivery System

May 14, 2025 05:53PM BioCardia (BCDA) Misses Q1 EPS by 59c

Apr 15, 2025 08:30AM BioCardia (BCDA) Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Trial

Apr 11, 2025 09:16AM BioCardia (BCDA) Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Mar 31, 2025 08:02AM BioCardia's (BCDA) Phase 3 CardiAMP-HF Trial Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

Mar 10, 2025 09:15AM BioCardia (BCDA) Announces Japanese Patent for Helix Biotherapeutic Delivery System

Feb 27, 2025 09:15AM BioCardia (BCDA) Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial

Feb 13, 2025 08:36AM BioCardia (BCDA) announce completed low dose enrollment for CardiALLO phase I/II

Dec 4, 2024 08:30AM BioCardia (BCDA) Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy

Nov 13, 2024 05:40PM BioCardia (BCDA) Misses Q3 EPS by 61c

Oct 28, 2024 09:03AM BioCardia (BCDA) Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

Sep 18, 2024 08:31AM BioCardia (BCDA) Regains Full Compliance with Nasdaq Listing Requirements

Aug 30, 2024 08:00AM BioCardia (BCDA) Prices Upsized 2.4M Share Offering at $3/sh

Aug 29, 2024 08:30AM BioCardia (BCDA) Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family

Aug 21, 2024 07:04AM BioCardia (BCDA)" FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 14, 2024 06:44AM BioCardiAa (BCDA) PT Raised to $25 at H.C. Wainwright

Aug 13, 2024 05:21PM BioCardia, Inc. (BCDA) Tops Q2 EPS by 12c

Jul 30, 2024 07:02AM BioCardia (BCDA) Submits for FDA Approval of Morph DNA

Jul 17, 2024 07:01AM BioCardia (BCDA) Receives US Patent on Morph DNA Multi-Directional Steerable Catheter Transseptal Application